Incidence of Bleeding in Renally Impaired Patients Receiving Incorrectly Dosed Eptifibatide or Bivalirudin While Undergoing Percutaneous Coronary Intervention

Abstract

Spanish

French

BACKGROUND:

Limited data are available regarding adverse bleeding events associated with antithrombotic agents incorrectly dosed based on renal function in patients receiving percutaneous coronary intervention (PCI).

OBJECTIVE:

To compare the incidence of bleeding during their hospital stay in patients with reduced renal function receiving incorrect doses of bivalirudin or eptifibatide to the incidence of correct doses, based on manufacturer recommendations; secondary objectives were to determine the incidence of correct dosing based on manufacturer recommendations and the incidence of TIMI (Thrombolysis in Myocardial Infarction) major bleeding.

METHODS:

A chart review over a 32-month period showed that patients with reduced renal function who received either eptifibatide or bivalirudin during PCI were evaluated for correct dosing based on manufacturer recommendations, bleeding incidence according to the TIMI criteria, and extent of bleeding according to the TIMI and GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) criteria.

RESULTS:

One hundred ninety patients met inclusion criteria, 56 who received eptifibatide and 134 who received bivalirudin. Eptifibatide was dosed incorrectly in 64% of the patients. Patients receiving incorrectly dosed compared to correctly dosed eptifibatide experienced significantly more bleeding (64% vs 35%, respectively, p = 0.04), a greater extent of bleeding based on the TIMI and GUSTO criteria (p = 0.03 and p = 0.009, respectively), and had more TIMI major bleeding (19% vs 5%, respectively). Bivalirudin was dosed incorrectly in 28% of the patients. Patients receiving incorrectly dosed compared to correctly dosed bivalirudin experienced a significantly greater extent of bleeding based on the GUSTO criteria (p = 0.01). There was no significant difference between the incidence of bleeding (37% vs 21%, respectively; p = 0.06), extent of bleeding based on the TIMI criteria (p = 0.058), or incidence of TIMI major bleeding (5% vs 3%).

CONCLUSIONS:

Patients receiving incorrectly dosed eptifibatide and bivalirudin are susceptible to adverse bleeding events. The occurrence of incorrect dosing offers an opportunity for pharmacist-driven institutional improvement.

Keywords

adverse events bivalirudin bleeding eptifibatide percutaneous coronary intervention

Get full access to this article

View all access options for this article.

References

Wright

Anderson

Adams

2011 ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2011;57:1920–59. DOI 10.1161/CIR.0b013e31820f2f3e.

2 Zeymer

Wienbergen

. A review of clinical trials with eptifibatide in cardiology. Cardiovasc Drug Rev 2007;25:301–15. DOI 10.1111/j.1527-3466.2007.00022.x.

Alexander

Chen

Roe

Excess dosing of antiplatelet and antithrombin agents in treatment of non–ST-segment elevation acute coronary syndromes. JAMA 2005;294:3108–16. DOI 10.1001/jama.295.6.628.

4 Robson

. The use of bivalirudin in patients with renal impairment. J Invasive Cardiol 2000;12:33F–6F.

Kirtane

Piazza

Murphy

Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. J Am Coll Cardiol 2006;47:2374–9. DOI10.1016/j.jacc.2005.09.080.

6 Roguin

Steinberg

Watkins

Resar

. Safety of bivalirudin during percutaneous coronary interventions in patients with abnormal renal function. Int J Cardiovasc Intervent 2005;7:88–92. DOI 10.1080/14628840510011298.

Tsai

Maddox

Roe

Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention. JAMA 2009;302:2458–64. DOI 10.1001/jama.2009.1800.

Chew

Bhatt

Kimball

Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol 2003;92:919–23. DOI 10.1016/S0002-9149(03)00970-6.

Chew

Lincoff

Germ

Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am J Cardiol 2005;95:581–5. DOI 10.1016/j.amjcard.2004.11.003.

10.

Reddan

O'Shea

Sarembock

Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial). Am J Cardiol 2003;91:17–21. DOI 10.1016/S0002-9149(02)02991-0.

11.

11 Rasty

Borzak

Tisdale

. Bleeding associated with eptifibatide targeting higher risk patients with acute coronary syndromes: incidence and multivariate risk factors. J Clin Pharmacol 2002;42:1366–73. DOI 10.1177/0091270002239367.

12.

Delhaye

Maluenda

Wakabayashi

Safety and in-hospital outcomes of bivalirudin use in dialysis patients undergoing percutaneous coronary intervention. Am J Cardiol 2010;105:297–301. DOI10.1016/j.amjcard.2009.09.030.

13.

Mudrick

Chen

Roe

Changes in glycoprotein IIb/IIIa inhibitor excess dosing with site-specific safety feedback in the Can Rapid risk stratification of Unstable angina patients Suppress Adverse outcomes with Early implementation of the ACC/AHA guidelines (CRUSADE) initiative. Am Heart J 2010;160:1072–8. DOI 10.1016/j.ahj.2010.08.008.

14.

14 Levey

Bosch

Lewis

Greene

Rogers

Roth

. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461–70.

15.

Rao

Pratt

Berke

Thrombolysis in Myocardial Infarction (TIMI) Trial–phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1–11.

16.

16An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993;329:673–82. DOI 10.1056/NEJM 199309023291001.

17.

17 Cockcroft

Gault

. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41. DOI 10.1159/000180580.

18.

18Product information. Integrilin (eptifibatide). Kenilworth, NJ: Schering-Plough; January 2009.

19.

19Product information. Angiomax (bivalirudin). Parsippany, NJ: The Medicines Company; December 2005.

20.

20The Joint Commission. 2010 National Patient Safety Goals (NPSGs). http://www.jointcommission.org/PatientSafety/NationalPatientSafety-Goals/ (accessed 2010 Sept 27).

21.

21 Wargo

English

. Evaluation of the Chronic Kidney Disease Epidemiology Collaboration equation for dosing antimicrobials. Ann Pharmacother 2010;44:439–46. DOI10.1345/aph.1M602.

22.

22 Roberts

Ibsen

Schioler

. Modified diet in renal disease method overestimates renal function in selected elderly patients. Age Ageing 2009;38:698–703. DOI 10.1093/ageing/ afp168.

23.

23 Gill

Malyuk

Djurdjev

Levin

. Use of GFR equations to adjust drug doses in an elderly multi-ethnic group–a cautionary tale. Nephrol Dial Transplant 2007;22:2894–9. DOI 10.1093/ndt/gfm289.

24.

Melloni

Peterson

Chen

Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non–ST-segment elevation acute coronary syndromes. J Am Coll Cardiol 2008;51:991–6. DOI10.1016/j.jacc.2007.11.045.

25.

25 Golik

Lawrence

. Comparison of dosing recommendations for antimicrobial drugs based on two methods for assessing kidney function: Cockcroft-Gault and Modification of Diet in Renal Disease. Pharmacotherapy 2008;28:1125–32. DOI 10.1592/phco.28.9.1125.

26.

26 Hermsen

Maiefski

Florescu

Qiu

Rupp

. Comparison of the Modification of Diet in Renal Disease and Cockcroft-Gault equations for dosing antimicrobials. Pharmacotherapy 2009;29:649–55. DOI 10.1592/phco.29.6.649.